Wassil Jim 4

What Happened
Jim Wassil, Chief Operating Officer of Vaxcyte, reported two open-market sales on June 1, 2026 totaling 2,250 shares for aggregate proceeds of approximately $111,415. The transactions were: 1,949 shares at a weighted-average price of $49.40 (≈ $96,288) and 301 shares at a weighted-average price of $50.26 (≈ $15,127). These were sales (not purchases), which are often routine or planned disposals rather than an explicit bullish signal.

Key Details

• Transaction date: June 1, 2026; Form 4 filed June 3, 2026 (appears timely).
• Sales: 1,949 shares @ weighted-average $49.40 (range $49.03–$49.93); 301 shares @ weighted-average $50.26 (range $50.205–$51.01).
• Total shares sold: 2,250; gross proceeds ≈ $111,415.
• Shares owned after transaction: not disclosed in the provided excerpt of the filing.
• Footnotes: (F1) Sales were executed under a Rule 10b5-1 trading plan adopted Dec 9, 2025. (F2/F3) Reported prices are weighted averages; per-price breakdowns are available on request to the SEC or issuer.

Context
A 10b5-1 plan lets insiders sell shares according to pre-set instructions and timing; such sales are generally viewed as routine and do not necessarily indicate the insider’s current view on the company. For retail investors, purchases typically carry more informational weight than planned sales.